CNMSC & Novartis Biomarkers Collaboration

The CNMSC has entered into a collaborative project with Novartis that spans 3 years. This exciting collaborative project was formed to advance MS clinician and clinic understanding and use of additional biomarkers beyond MRI to monitor MS patients in Canada.

Summary of activities 2025-2026:

  • Negotiation of a collaborative project agreement between Novartis and CNMSC
  • Formation of biomarker working group CNMSC
    • CNMSC Working Group Members
      • Dr. Penny Smyth
      • Dr. Mark Freedman
      • Dr. Philip Beuachemin
      • Dr. Jiwon Oh
      • Dr. Alexandra Muccilli
      • Dr. Fraser Clift
      • Dr. Jodie Roberts
  • Co-creation of biomarker survey - sent out to CNMSC Dec 2024/Jan 2025
  • Review and summary of biomarker survey results by Biomarker working group Feb 2025
  • Review of biomarker survey with Novartis Final sNfL survey Feb 2025 Slide Deck.pdf
  • Incorporation of the use of biomarkers into CNMSC fellow presentation June 2025
  • Initiation of updated Canadian Treatment Optimization Guidelines April 2025 and assignment of working groups, including guidelines on the use of biomarkers
CNMSC logo
Novartis logo